Research & Development
US regulators authorise Pfizer/BioNTech's COVID-19 vaccine for use in children aged 12 to 15
11 May 2021 -

US regulators have authorised US pharmaceutical company Pfizer Inc (NYSE:PFE) and its partner, German bio technology company BioNTech SE's (Nasdaq:BNTX) COVID-19 vaccine for use in children as young as 12, Reuters news agency reported on Tuesday.

The regulators also said they could begin receiving the COVID-19 vaccine as soon as 13 May 2021.

Reportedly, this is the first COVID-19 vaccine to be authorised in the US for ages 12 to 15. Vaccinating younger ages is considered an important step for getting children back into schools safely.

US President Joe Biden has asked states to make the vaccine available to younger adolescents immediately.

This vaccine has been available under an emergency use authorisation to people as young as 16 in the US. The companies said they had started seeking full approval for the immunization in people 16 and older last week.

The director of the US Food and Drug Administration's Centre for Biologics Evaluation and Research was quoted as telling reporters that states will likely be able to begin vaccinating 12 to 15-year-olds after an advisory committee of the US Centres for Disease Control and Prevention considers the expansion on 12 May 2021.



Related Headlines